The European Commission has signed a contract with the American pharmaceutical company “Eli Lilly” for the supply of a preparation with monoclonal antibodies for the treatment of patients with coronavirus, the EC press service announced.
The drug was part of the first portfolio of five promising therapeutic agents announced by the Commission in June in its Covid-19 Treatment Strategy.
The medicine is currently being examined by the European Medicines Agency. 18 Member States have joined the joint procurement for the purchase of over 220,000 therapeutic doses.
Health Commissioner Stella Kyriakidou said more than 73 per cent of the adult population in the community was fully vaccinated. However, she warned that vaccines could not be the only answer against the coronavirus and that work should continue to provide treatment.
In addition to Eli Lilly, the EC has already signed contracts for the supply of coronavirus drugs with manufacturers Roche (Switzerland) and GlaxoSmithKline (UK).
The American company’s preparation is a combination of two monoclonal antibodies for the treatment of patients who do not need oxygen therapy, but are at high risk of severe Covid-19.
